Form 4: MAIA Biotechnology Director Stan Smith Acquires Shares and Warrants

Director Stan Smith reports purchasing MAIA Biotechnology common stock and warrants, increasing his indirect beneficial ownership.

Summary

• On May 8, 2025, Stan Smith, a director of MAIA Biotechnology, Inc., acquired 66,666 shares of common stock at $1.50 per share.
• He also acquired 66,666 warrants with an exercise price of $2.05.
• These transactions increased his indirect beneficial ownership through The Stan V. Smith Trust Dated 1993.
• Following the reported transactions, Smith beneficially owns 1,271,726 shares of common stock indirectly.
• The warrants are exercisable beginning on May 8, 2026, and expire on May 8, 2031.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares and warrants suggests confidence, but it's a routine disclosure.

Positives

• A director's purchase of shares and warrants can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing indicates a director's recent investment in MAIA Biotechnology.

Stakeholder Impact

• The increased insider ownership could be viewed positively by shareholders.

Key Dates

Keywords

MAIA Biotechnology, Stan Smith, Director, Beneficial Ownership, Form 4, Securities Purchase Agreement, Warrants, Common Stock, Equity Incentive Plan